HRT FINANCIAL LP, identified as holding a 10% stake in Onconetix, Inc. (NASDAQ:ONCO), disclosed a cluster of transactions in the company’s Class A common shares during mid-April. Over several days the firm sold shares amounting to $110,169 and also purchased a smaller block worth $25,284.
The sales and purchase took place at prices between $0.73 and $0.75 per share. On April 16, 2026, HRT sold 53,867 Class A shares at $0.73 each. The following day, April 17, 2026, the firm acquired 34,636 Class A shares at $0.73 per share, an acquisition totaling $25,284. A subsequent sale on April 20, 2026, saw HRT dispose of 94,462 Class A shares at $0.75 per share.
After these reported trades, HRT FINANCIAL LP directly holds 83,359 Class A shares of Onconetix. The net activity reduces the firm’s exposure by the amounts sold while adding the mid-sequence purchase to its position.
The disclosed trading comes as Onconetix shares are trading close to their 52-week low of $0.67. The stock has fallen by nearly 20% over the most recent week. According to InvestingPro analysis referenced in the company disclosures, the shares carry a Fair Value estimate of $1.09, implying a gap between current market pricing and that analytic valuation. InvestingPro also lists 17 additional ProTips for ONCO, which include observations about the company’s cash position and patterns of volatility.
Several operational and corporate items involving Onconetix and related parties were also detailed. Onconetix is in the process of acquiring Realbotix Corp., which has stated it expects to deliver 19 robots by May 2026 as part of scaling its production capacity. Separately, Onconetix named David White as its new chief executive officer and added Sammy Dorf to its board of directors. White is described as bringing over three decades of leadership experience to the role.
Realbotix achieved a milestone when one of its robots was used in a 6G trial at Ericsson’s U.S. headquarters; that deployment represented Realbotix’s first enterprise client relationship with Ericsson and showcased AI-driven robotics paired with real-time video streaming over a wireless network.
Onconetix also announced a 1-for-5 reverse stock split that will change the share count and trading characteristics of its common stock.
Clear summary
HRT FINANCIAL LP executed mid-April trades in Onconetix Class A shares that produced $110,169 in sales and a $25,284 purchase, leaving the firm with 83,359 shares. These moves unfolded as Onconetix stock approached a 52-week low and amid corporate developments tied to a Realbotix acquisition, leadership changes, and a reverse split.
Key points
- HRT FINANCIAL LP sold 53,867 Class A shares on April 16, 2026 at $0.73 and 94,462 shares on April 20, 2026 at $0.75, and bought 34,636 shares on April 17, 2026 at $0.73.
- Post-transactions, HRT directly holds 83,359 Class A shares of Onconetix.
- Onconetix is pursuing the acquisition of Realbotix, has appointed a new CEO and a board addition, and announced a 1-for-5 reverse stock split; Realbotix is preparing to deliver 19 robots by May 2026 and participated in a 6G trial with Ericsson.
Risks and uncertainties
- Share price volatility: Onconetix shares are near a 52-week low of $0.67 and have fallen nearly 20% in the past week, indicating elevated short-term volatility that could affect shareholders and market liquidity - relevant to equity and small-cap market participants.
- Execution risk around the acquisition and integration of Realbotix: Ongoing corporate actions such as the acquisition and related operational milestones (including Realbotix’s planned deliveries) introduce uncertainty for both companies’ operational and financial outcomes - relevant to technology, robotics, and corporate finance stakeholders.
- Capital structure change: The announced 1-for-5 reverse stock split will alter the company’s share count and trading characteristics, which may affect investor perception and liquidity - relevant to equity markets and current shareholders.
For readers tracking insider transactions and corporate developments, these disclosed trades and the surrounding company actions provide context but do not, by themselves, indicate definitive outcomes for Onconetix’s operational or market performance.